687 results about "Antiserum" patented technology

The present invention is directed to the cloning, sequencing and expression of homologous immunoreactive 28-kDa protein genes, p28-1, -2, -3, -5, -6, -7, -9, from a polymorphic multiple gene family of Ehrlichia canis. Further disclosed is a multigene locus encoding all nine homologous 28-kDa protein genes of Ehrlichia canis. Recombinant Ehrlichia canis 28-kDa proteins react with convalescent phase antiserum from an E. canis-infected dog, and may be useful in the development of vaccines and serodiagnostics that are particularly effective for disease prevention and serodiagnosis.

Non-infectious, retrovirus-like particles comprise an assembly of an env gene product, a pol gene product and a gag gene product contain an antigenic marker which is non-retroviral or non-HIV retroviral. In one embodiment, the marker comprises an amino acid sequence containing an epitope inserted into the gag gene product at an antigenically-active insertion site. In another embodiment, the marker comprises an antigenic anchor sequence operatively connected to the env gene product replacing endogenous anchoring function. The corresponding nucleic acid molecules are described. The non-infectious, retrovirus-like particles have utility in in vivo administration including to humans and in diagnosis. The presence of the antigenic marker enables recognition that antiserum containing anti-retroviral antibodies has been generated by exposure to the non-infectious retrovirus-like particles by testing for antibodies specific to the antigenic marker.

The invention discloses a method of preparing a bombyx mori silk fibroin specific antibody by utilizing a characteristic polypeptide. The method comprises the following steps: synthesizing a "CGAGAGSGAGAGS" polypeptide sequence by utilizing an Fmoc method, coupling the polypeptide with keyhole limpet hemocyanin (KLH) through the cysteine on the N terminus of the polypeptide so as to obtain a complete antigen; diluting the complete antigen with normal saline, mixing the diluted complete antigen with a complete Freund's adjuvant, adding streptomycin and penicillin to carry out an emulsion treatment so as to obtain a primary immunized antigen emulsion, subjecting a rabbit to a primary immunization by using the primary immunized antigen emulsion, then subjecting the rabbit to a strengthened immunization, wherein the strengthened immunization uses a strengthened immunized antigen emulsion, which is prepared by the following steps: mixing the diluted complete antigen with an incomplete Freund's adjuvant, and then adding streptomycin and penicillin to carry out an emulsion treatment so as to obtain the target product; collecting the blood of the immunized rabbit, when the antibody titer in the rabbit blood sample reaches 1/10000; making the blood blocks fully contract to completely separate out the antiserum, then collecting the antiserum, and subjecting the antiserum to a centrifugation treatment so as to obtain a supernate.

The invention belongs to the technical field of biological engineering and in particular is a heat-induced fusion expression recombinant plasmid of truncated GST protein and a process for preparation. The invention selects utility truncated GST188 protein which is composed of 188aa as a carrier, a pXXGST-1 recombinant plasmid which expresses short peptide fusion protein in an escherichia coli heat-induced expression system and a heat-induced type pXXGST-2 recombinant plasmid which is used to express comparison to realize the aim of synthesizing short peptide creatures, which is especially provided for scanning, drawing, positioning antigen linear epitopes and identifying epitope motif. Experiments of the invention prove the adaptability and the applicability of the GST188 core protein which is used as the short peptide creatures expression vector, in antigen epitope scanning identification, and in particular when anti- recombinant target protein antiserum is used to indentify the epitope motif.

The invention discloses an E.tenella protein disulfide linkage isomerase gene EtPDI (Clone ID is BW1-E06,and the Genbank accession number of is EF552214). The gene is connected with a procaryon expression vector pGEX-4T-2; a procaryon expression recombination plasmid pGEX-4T-EtPDI is constructed and is expressed in a colibacillus system; and most of the expressed recombining protein exists in a soluble form. The recombining protein 4T-EtPDI is purified to carry out SPS-PAGE and is transferred to a PVDF film; and antiserum of E.tenella oocyst oral immunized chicken is used as first resistance and goat anti-chicken IgG is used as second resistance to carry out Western-blot analysis, thereby indicating that the gene has certain antigen. The gene is used for preparing an anti-chicken coccidiosis drug and an anti-chicken coccidiosis vaccine.

The invention relates to polyethylene glycol monomethyl ether-poly 2-methyl-carboxyl propylene carbonate graft polyethyleneimine copolymer, a preparation method thereof and application thereof. The preparation method comprises the step of directly condensing carboxyl in the polyethylene glycol monomethyl ether-poly 2-methyl-carboxyl propylene carbonate graft polyethyleneimine segmented copolymer with amino in polyethyleneimine to form the graft copolymer. The copolymer is a polycation gene carrier, integrates the advantages of polyethylene glycol, Makrolan and polyethyleneimine, and has high transfection efficiency, wherein the highest transfection efficiency to the medium luciferase plasmid of african green monkey kidney cell is 14 times of that of American Invitrogen biological company transfection reagent Lipofetamine<TM>2000, can effectively antagonize the inhibiting effect of blood serum to the transfection, and has less cell toxicity, wherein consistency thereof is not higher than 200 microgramme/ml and cell survival rate is more than 80%.

The present invention discloses one kind of retinol conjugated protein and its preparation process and specific antibody. The present invention expresses retinol conjugated protein effectively for the first time, and the expressed retinol conjugated protein has property near to that of natural retinol conjugated protein (RBP4). Immunizing animal with the expressed retinol conjugated protein can obtain antibody capable of recognizing natural retinol conjugated protein in human body sensitively. The present invention fills in a gap in RBP4 antiserum.

This invention relates to hydrochloric acid CLB enzyme immunity test reagent box and its test method adopting ELISA competition to test CLB and using CLB and OA coupler as CLB antigen immunity rabbits to small mouses to get multiclonal containing CLB antibody or monoclonal CLB antiserum then to be put on enzyme specimen board after separation, purification and dilution to be warm cultivated, washed, added with sample diluent solution and enzyme specimen antigen to be reacted, washed and added with enzyme substrate to display color. It is an easy test method with simple pretreatment especially for testing remaining CLB of meat food.

The invention relates to a polyclonal antibody for detecting the residue and the degradation of a CP4-EPSPS protein in a processed food and application thereof. An animal is immunized by using a CP4-EPSPS protein peptide segment of a coupled keyhole limpet hemocyanin (KHL) to obtain antiserum, namely the antibody of the invention. The application comprises a Western blotting and a colloidal gold test strip and has the characteristics of simplicity, practicability, high sensitivity and the like, wherein the Western blotting is used for detecting the residue and the degradation of the CP4-EPSPS protein in food; and test strip technology is used for the rapid detection of the CP4-EPSPS protein in the food. The invention provides a high-practicability method for the safety detection of a genetically modified food, and has a very high practical application value.

The present invention provides a non-human animal-derived antiserum and/or non-human animal-derived immunoglobulin against the 2019-nCOV (SARS-CoV-2). The invention is intended to be able to be used in the treatment and prevention of novel coronavirus pneumonia.

The invention relates to a human papilloma virus capsid protein L1 (HPVL1) peptide and preparation and application thereof. The HPVL1 peptide is a peptide segment of which the amino acid of the sequence is N end-Cys Thr Leu Thr Ala Asp Val Met listed Thr Tyr Ile His-C end, or is a peptide segment comprising the amino acid of the sequence and with a length less than 50 amino acids. In the invention, the peptide which is a very conservative peptide segment located on the surface of protein is sieved out by performing epitope forecasting and multi-sequencing comparison on the L1 proteins of 18 low-risk types and high-risk type HPV subtypes (6, 11, 16, 18, 52, 58 and the like); the antibody generated from induction can react with multiple types of HPVL1, and can be used for the detection of the multiple types of HPVL1, in particular to the application of precancerous lesions detection of human cervical carcinoma; and the antibody aiming at the peptide segment also can be used for purifying and preparing the multiple types of HPVL1. In addition, the invention also provides the applications of the peptide segment used as multiple types of HPV antiserum and detected matters of monoclonal antibody.

The invention discloses half antigen and antigen of tenuazonic acid and a preparation method and application thereof. The antigen can serve as a compound of the tenuazonic acid half antigen and is provided with the structure as the formula I. The antigen of the tenuazonic acid is obtained by mixing TeAH and carrier protein, dissolving carrier protein into phosphate buffer solution (PBS), droppingglutaraldehyde solution, conducting stirring and reaction and then conducting dialysis through physiological saline, or the ntigen of the tenuazonic acid is obtained by dissolving TeAHGA into N, N-dimethylformamide, adding bicyclocaproyl carbodiimide and N-hydroxy succinimide into the mixture, stirring the liquid, conducting centrifugation to obtain supernatant as A liquid, dissolving carrier protein in the PBS, stirring and dissolving the PBS to obtain B liquid, dropping the A liquid into the B liquid for reaction and conducting dialysis through physiological saline. The antiserum valence obtained by antigen immune animals can reach 1: 3.2*104, the linear range of TeAH ranges from 0.130ng/mL to 8.789ng/mL(IC20-IC80), the half inhibition concentration is 1.095ng/mL, and the produced antigen is high in specificity, high in sensitivity and high in accuracy. Formula I.

The invention discloses a Coxsackie virus A6 strain (WF057R) and applications thereof. The preservation number of the Coxsackie virus A6 strain (WF057R) in China General Microbiological Culture Collection Center (CGMCC) is CGMCC No.13393. A vaccine and CVA6 antiserum prepared from WF057R can treat and prevent diseases caused by CVA6. Furthermore, the maternal-transferred antibody of WF057R also has a protective effect on newborn mice. WF057R can also be used to establish a stable Coxsackie virus A6 infected animal model with good repeatability, and the animal model can be applied to drug antivirus treatment and immune protective effect evaluation of viral inactivation vaccines.

Provided herein are a hybridoma cell line producing monoclonal antibody against foot-and-mouth disease virus (FMDV), the monoclonal antibody therefrom, reagent and kit for ELISA, and immunoassay method. The hybridoma cell line is produced by cell fusion of a parental cell and a myeloma cell line and has the same characteristics as the cell line whose strain designation is CmA40 and deposition number is ATCC (To be Provided). The parental cell is a splenocyte isolated from the spleen of a mouse immunized by an antigen derived from a 3ABC non-structural protein (NSP) of FMDV. The antigen used here is expressed by a prokaryotic cell. The monoclonal antibody produced by the hybridoma cell line can specifically recognize a 3ABC polypeptide and does not cross-react with an antiserum of swine vesicular disease virus.

The invention provides a kit for detecting serum amyloid A content and a preparation method and detection method thereof and belongs to the field of medical detection. The kit comprises a hemolytic agent R1 and a latex reagent R2 which are independent with each other. The latex reagent R2 comprises latex coated with a serum amyloid A antibody. The latex coated with the serum amyloid A antibody isprepared from latex having particle sizes of 60-130nm and coated with the anti-serum amyloid A1 antibody and latex having particle sizes of 190-220nm and coated with the anti-serum amyloid A2 antibodythrough mixing. The invention also provides a preparation method and a detection method of the kit for detecting serum amyloid A content. The kit can detect whole blood, serum, a cerebrospinal fluidand a pleuroperitoneal fluid, utilizes a small amount of samples, is free of separation or pretreatment, can be directly used for detection and has good sample compatibility.

This invention discloses monoclonal antibody against anti-LCDV immunoglobulin of Paralichthys olivaceus, which is excreted by hybridoma JF-lgM-H (CCTCC-C200631). The method comprises: immunizing Paralichthys olivaceus with LCDV inactivated by formalin to prepare antiserum, purifying Paralichthys olivaceus immunoglobulin, immunizing Balb/c mice as antigen, preparing hybridoma cells by cell engineering method, and screening the monoclonal antibody by immunoassay. Indirect ELISA and indirect immunofluorescent antibody assay show that this monoclonal antibody is located on the heavy chain (7-80 kDa) of the anti-LCDV immunoglobulin. The monoclonal antibody can be used for preparing reagents for detecting LCDV infection in early stage, and evaluating the immune effects of LCDV vaccine inactivated by formalin.

Methods and products are described for inducing B cell apoptosis, using antibody-induced apoptosis. Specifically, polyclonal antiserum or one or more monoclonal antibodies, either alone or in combination, as well as fragments or variants thereof are employed in the methods and products of the present invention. These antibodies, or fragments or variants thereof, are capable of binding to B cell surface markers under conditions effective to collectively or individually induce apoptosis of the contacted B cell. Consequently, the methods and products of the present invention can be used therapeutically to treat, or as a preventative agent to protect against, a B cell-related condition or disorder.

The invention belongs to the field of biological engineering, and provides a kit for detecting the concentration of a complement Clq in human serum by an immune transmission turbidimetry and an immune scattering turbidimetry. The kit solves the technical problems that an immune diffusion method and an enzyme-linked immune sorbent assay (ELISA) double antibody sandwich technology for measuring theconcentration of the complement Clq have complicated steps and are low in accuracy and repeatability in the prior art. The kit comprises two reagents, wherein a first reagent consists of disodium hydrogen phosphate, monopotassium phosphate, polyethylene glycol 6000 (PEG6000), ethylene diamine tetraacetic acid (EDTA)-NA2 and TX-100; and a second reagent consists of the disodium hydrogen phosphate,the monopotassium phosphate, the PEG 6000, the EDTA-NA2, the TX-100 and rabbit antihuman complement Clq antiserum. The invention also provides a method for detecting the concentration of the complement Clq in the human serum by using the kit. The kit and the method for measuring the concentration of the complement Clq have simple and convenient steps, are high in accuracy and repeatability and are used for automated analysis meters.